Eroxon, the first-ever, FDA-cleared gel available without a prescription for the treatment of erectile dysfunction (ED), will be available effective Tuesday, Oct. 1, through Amazon and major retail pharmacies nationally Oct. 1, according to Haleon the manufacturer.
Dr. Joshua Gonzalez, a urologist in the Los Angeles area and spokesman for Haleon, said Eroxon potentially can be a first-line treatment for men with ED (erectile dysfunction), potentially displacing medicines such as Viagra and Cialis.
“Eroxon is clinically proven to help men get an erection within 10 minutes, addressing a significant unmet need in the ED market with a majority of current treatment and care options taking up to an hour to work (based on labels).”
The treatment stimulates nerve endings in the penis to help men with ED get and maintain an erection during sex.
Clinical research shows that the gel is safe and effective in men with ED. While ED can be caused by underlying physical conditions, psychological challenges such as stress, anxiety, depression, and other mental health issues may also contribute to ED, especially in younger men.
In two clinical trials, more than 60% of participants experienced a meaningful improvement in their erections. Eroxon is safe for men and their partner.
Application can be used as a part of foreplay. In a clinical study, partners applied the product for the male as part of foreplay, resulting in better outcomes compared to men that did not have a partner apply the treatment during foreplay.
The gel contains a combination of volatile solvents which, when applied to the head of the penis, evaporate rapidly, stimulating nerve endings through an initial cooling effect followed by a warming sensation. This reaction releases nitric oxide, relaxing the smooth muscle tissue inside the penis and increasing blood flow that is needed to obtain an erection.
In rare cases, Eroxon may cause a burning or itching sensation. Seek medical attention if the irritation continues.
How to use Eroxon.
Unscrew cap. Pierce the tube seal with top of cap.
Squeeze tube firmly to empty all the contents onto finger(s), which will provide the correct dose.
Massage the gel onto the head of your penis for about 15 seconds. If you are uncircumcised, gently pull your foreskin back as far as comfortable before applying the gel. It may take a few attempts to achieve the desired effect.
You can apply the gel, or your partner can apply the gel to your penis as part of foreplay. In a clinical study, partners applied the product for the male as part of foreplay, which resulted in better outcomes.
Nationally, 30 million (one in five) U.S. men over 22 have ED. ED is a major problem for men of all ages, though those above 65—the age when many are diagnosed with prostate cancer.
In men with prostate cancer who have undergone radical prostatectomy, there is a tendency to blame it on the operation. But ED also can affect men on Active Surveillance, who have not undergone treatment because ED can be affected by aging.
The heart
Gonzalez said: “The main cause of ED in men over 65 is definitely cardiovascular dysfunction. The penis is a vascular organ and often susceptible earlier than other areas of the body to declines in cardiovascular health. Atherosclerosis causing diminished blood flow to the penis can interfere with normal erectile function. And this can often be the first sign of cardiovascular dysfunction, which is sometimes related to comorbidities like hypertension and diabetes.”
He added: “The prevalence of ED increases with age, going up by about 10% with each decade of life. It is estimated that 30% of men in their 30s have experienced ED, 40% in their 40s, 50% in their 50s, and so on. The issues that contribute to ED are similar for younger and older men. These include psychological factors as well as hormonal, vascular, and neurological issues. Younger men may be at greater risk for psychologically driven ED.”
Joshua Gonzalez, MD
“Men who have undergone RP have plenty of options including oral medications like Cialis and Viagra, which have an overall success rate of 70-90%. Their effectiveness may be lower in men who have undergone RP, but those men can still use intracavernosal injectable medications that treat ED. These medications are typically injected directly into the penis right before sexual activity and can work more reliably than the oral medications for some men. Men who do not respond to medications can always consider penile implant surgery,” said Gonzalez.
I reported on the latest trial on the in Medscape in reporting in May on the American Urological Association.
Wayne Hellstrom, MD, chief of andrology at Tulane School of Medicine in New Orleans, who presented the study of Eroxon, told me the gel is considered to be a device by the US Food and Drug Administration, which cleared the product in June 2023.
Hellstrom said the gel acts differently than PDE5 (Phosphodiesterase 5 Inhibitors," which are vasodilating drugs that stimulate the corpora cavernosa of the penis, facilitating erection with sexual stimulation.
He noted that some men men cannot use PDe5s and the meds are not tolerated by others and are not completely effective. They can take effect in one to two hours. About half of patients quit these drugs within a year.
Kevin McVary, MD, a professor of urology at Stritch School of Medicine of Loyola University, outside of Chicago, and director of the Center for Male Health, told Medscape he was skeptical.
McVary said that men with erectile dysfunction will probably do anything to avoid seeing a physician about the condition, which could make the new product highly marketable.
However, he stressed that examinations would be important to detect unrecognized underlying cardiac disease, especially in younger men. "ED can function as the classic canary in a coal mine where it tells you who's at risk for unexpected early death," he said.
Amazon charges $26 for four single-use tubes.
Haleon's U.S. brands include Abreva, Advil, Benefiber, Centrum, Emergen-C, Excedrin, Flonase, Gas-X, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, and Voltaren.
Still time to registerActive Surveillance for prostate cancer – the past, the present, and the future. Sstarts at noon EST Saturday, Sept. 28.
Peter Carroll, MD, MPH, of the University of California, San Francisco, one of the pioneers of Active Surveillance for low-risk prostate cancer, in the late 1990s, will be speaking to Active Surveillance Patients International at noon Eastern on Saturday Sept. 28, 2024.
His program is entitled “Active Surveillance for prostate cancer – the past, the present, and the future.”
Carroll is the 2024 recipient of Active Surveillance Patients International’s Chodak Award honoring pioneers in the development of the Active Surveillance approach to managing lower-risk prostate cancer. The award is named for the late Gerald Chodak, MD, of the University of Chicago, he laid down the fundamentals for a more conservative approach to managing these patients. Chodak was ASPI’s first medical advisor.
The Active Surveillor is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Share this post
New OTC treatment for ED. Will it displace 'those little blue pills' as 1st-line treatment?
Share this post
By Howard Wolinsky
Eroxon, the first-ever, FDA-cleared gel available without a prescription for the treatment of erectile dysfunction (ED), will be available effective Tuesday, Oct. 1, through Amazon and major retail pharmacies nationally Oct. 1, according to Haleon the manufacturer.
Dr. Joshua Gonzalez, a urologist in the Los Angeles area and spokesman for Haleon, said Eroxon potentially can be a first-line treatment for men with ED (erectile dysfunction), potentially displacing medicines such as Viagra and Cialis.
“Eroxon is clinically proven to help men get an erection within 10 minutes, addressing a significant unmet need in the ED market with a majority of current treatment and care options taking up to an hour to work (based on labels).”
The treatment stimulates nerve endings in the penis to help men with ED get and maintain an erection during sex.
Clinical research shows that the gel is safe and effective in men with ED. While ED can be caused by underlying physical conditions, psychological challenges such as stress, anxiety, depression, and other mental health issues may also contribute to ED, especially in younger men.
In two clinical trials, more than 60% of participants experienced a meaningful improvement in their erections. Eroxon is safe for men and their partner.
Application can be used as a part of foreplay. In a clinical study, partners applied the product for the male as part of foreplay, resulting in better outcomes compared to men that did not have a partner apply the treatment during foreplay.
The gel contains a combination of volatile solvents which, when applied to the head of the penis, evaporate rapidly, stimulating nerve endings through an initial cooling effect followed by a warming sensation. This reaction releases nitric oxide, relaxing the smooth muscle tissue inside the penis and increasing blood flow that is needed to obtain an erection.
In rare cases, Eroxon may cause a burning or itching sensation. Seek medical attention if the irritation continues.
How to use Eroxon.
Unscrew cap. Pierce the tube seal with top of cap.
Squeeze tube firmly to empty all the contents onto finger(s), which will provide the correct dose.
Massage the gel onto the head of your penis for about 15 seconds. If you are uncircumcised, gently pull your foreskin back as far as comfortable before applying the gel. It may take a few attempts to achieve the desired effect.
You can apply the gel, or your partner can apply the gel to your penis as part of foreplay. In a clinical study, partners applied the product for the male as part of foreplay, which resulted in better outcomes.
Nationally, 30 million (one in five) U.S. men over 22 have ED. ED is a major problem for men of all ages, though those above 65—the age when many are diagnosed with prostate cancer.
In men with prostate cancer who have undergone radical prostatectomy, there is a tendency to blame it on the operation. But ED also can affect men on Active Surveillance, who have not undergone treatment because ED can be affected by aging.
The heart
Gonzalez said: “The main cause of ED in men over 65 is definitely cardiovascular dysfunction. The penis is a vascular organ and often susceptible earlier than other areas of the body to declines in cardiovascular health. Atherosclerosis causing diminished blood flow to the penis can interfere with normal erectile function. And this can often be the first sign of cardiovascular dysfunction, which is sometimes related to comorbidities like hypertension and diabetes.”
He added: “The prevalence of ED increases with age, going up by about 10% with each decade of life. It is estimated that 30% of men in their 30s have experienced ED, 40% in their 40s, 50% in their 50s, and so on. The issues that contribute to ED are similar for younger and older men. These include psychological factors as well as hormonal, vascular, and neurological issues. Younger men may be at greater risk for psychologically driven ED.”
Joshua Gonzalez, MD
“Men who have undergone RP have plenty of options including oral medications like Cialis and Viagra, which have an overall success rate of 70-90%. Their effectiveness may be lower in men who have undergone RP, but those men can still use intracavernosal injectable medications that treat ED. These medications are typically injected directly into the penis right before sexual activity and can work more reliably than the oral medications for some men. Men who do not respond to medications can always consider penile implant surgery,” said Gonzalez.
I reported on the latest trial on the in Medscape in reporting in May on the American Urological Association.
Wayne Hellstrom, MD, chief of andrology at Tulane School of Medicine in New Orleans, who presented the study of Eroxon, told me the gel is considered to be a device by the US Food and Drug Administration, which cleared the product in June 2023.
Hellstrom said the gel acts differently than PDE5 (Phosphodiesterase 5 Inhibitors," which are vasodilating drugs that stimulate the corpora cavernosa of the penis, facilitating erection with sexual stimulation.
He noted that some men men cannot use PDe5s and the meds are not tolerated by others and are not completely effective. They can take effect in one to two hours. About half of patients quit these drugs within a year.
Kevin McVary, MD, a professor of urology at Stritch School of Medicine of Loyola University, outside of Chicago, and director of the Center for Male Health, told Medscape he was skeptical.
McVary said that men with erectile dysfunction will probably do anything to avoid seeing a physician about the condition, which could make the new product highly marketable.
However, he stressed that examinations would be important to detect unrecognized underlying cardiac disease, especially in younger men. "ED can function as the classic canary in a coal mine where it tells you who's at risk for unexpected early death," he said.
Amazon charges $26 for four single-use tubes.
Haleon's U.S. brands include Abreva, Advil, Benefiber, Centrum, Emergen-C, Excedrin, Flonase, Gas-X, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, and Voltaren.
Still time to registerActive Surveillance for prostate cancer – the past, the present, and the future. Sstarts at noon EST Saturday, Sept. 28.
Peter Carroll, MD, MPH, of the University of California, San Francisco, one of the pioneers of Active Surveillance for low-risk prostate cancer, in the late 1990s, will be speaking to Active Surveillance Patients International at noon Eastern on Saturday Sept. 28, 2024.
His program is entitled “Active Surveillance for prostate cancer – the past, the present, and the future.”
REGISTER HERE
Carroll is the 2024 recipient of Active Surveillance Patients International’s Chodak Award honoring pioneers in the development of the Active Surveillance approach to managing lower-risk prostate cancer. The award is named for the late Gerald Chodak, MD, of the University of Chicago, he laid down the fundamentals for a more conservative approach to managing these patients. Chodak was ASPI’s first medical advisor.
The Active Surveillor is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.